Amgen Inc. is a leading independent biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. The company addresses critical needs for patients with serious illnesses, including rare diseases, cancer, and cardiovascular diseases. Amgen leverages its expertise in human genetics, novel biology, and protein engineering to develop first-in-class medicines. Established over 40 years ago, Amgen operates in approximately 100 countries worldwide.

Amgen's growth strategy involves continuous innovation, strategic acquisitions (such as the recent acquisition of Horizon Therapeutics plc), and expansion into new markets. The company's competitive advantage lies in its manufacturing capabilities, R&D expertise, and global presence. Amgen focuses on developing therapies with strong safety and efficacy profiles, reliable supply, and convenient delivery devices. The company also emphasizes patient support and education programs and collaborates with payers to improve healthcare outcomes.

Amgen faces competition from other biopharmaceutical companies, including those developing biosimilars and generics. The company actively seeks to differentiate its products through innovation, expanding treatment indications, and improving drug delivery and manufacturing processes. Amgen also develops and markets biosimilar products, competing against both branded and biosimilar versions of competitors' products.

• Employees: 26,700 (as of December 31, 2023)
• Geographic Footprint: 50+ countries
• Headquarters: Thousand Oaks, California
• Founded: 1980 (Incorporated in California), 1987 (Became a Delaware corporation)
• Number of locations/facilities: ~160
• Revenue: $28.2 billion (FY2023)
• Key Subsidiaries/Brands: Horizon Therapeutics plc, ChemoCentryx, Inc., Five Prime Therapeutics, Inc., Teneobio, Inc.

• CEO & Chairman: Robert A. Bradway
• Executive VP, R&D & Chief Scientific Officer: James E. Bradner
• Executive VP, Global Commercial Operations: Murdo Gordon
• Executive VP, General Counsel & Secretary: Jonathan P. Graham
• Executive VP & CFO: Peter H. Griffith
• Senior VP & Chief Compliance Officer: Nancy A. Grygiel
• Senior VP, Business Development: Rachna Khosla
• Senior VP, Human Resources: Derek Miller
• Executive VP & Chief Technology Officer: David M. Reese
• Executive VP, Operations: Esteban Santos

• Annual Revenue: $28.2 billion (FY2023)
• Net Income: $6.7 billion (FY2023)
• Total Assets: $97.2 billion (FY2023)
• Number of Employees: 26,700 (as of December 31, 2023)
• Key Financial Highlights (FY2023):
  • 9% increase in total product sales
  • Acquisition of Horizon Therapeutics plc for $27.8 billion
  • 10% increase in quarterly cash dividend to $2.13 per share
  • Cash flows from operating activities totaled $8.5 billion

Amgen develops, manufactures, and markets a diverse portfolio of human therapeutics for serious illnesses. Key products and brands include:

• Prolia/XGEVA (denosumab): Treatment of osteoporosis in postmenopausal women and men and for the prevention of skeletal-related events in patients with bone metastases.
• Enbrel (etanercept): Treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.
• Otezla (apremilast): Treatment of plaque psoriasis, psoriatic arthritis, and Behçet's disease.
• Repatha (evolocumab): PCSK9 inhibitor for reducing cardiovascular risks.
• KYPROLIS (carfilzomib): Treatment of relapsed or refractory multiple myeloma.
• Aranesp (darbepoetin alfa): Treatment of anemia caused by chronic kidney disease.
• EVENITY (romosozumab-aqqg): Treatment of osteoporosis in postmenopausal women and men at high risk of fracture.
• Vectibix (panitumumab): Treatment of metastatic colorectal cancer.
• BLINCYTO (blinatumomab): Treatment of acute lymphoblastic leukemia.
• TEPEZZA (teprotumumab-trbw): Treatment of thyroid eye disease.
• KRYSTEXXA (pegloticase): Treatment of chronic refractory gout.
• UPLIZNA (inebilizumab-cdon): Treatment of neuromyelitis optica spectrum disorder.
• Biosimilars: MVASI (bevacizumab), KANJINTI (trastuzumab), AMJEVITA/AMGEVITA (adalimumab), AVSOLA (infliximab), RIABNI (rituximab), BEKEMV (eculizumab), Wezlana (ustekinumab biosimilar).

Amgen operates in one business segment: human therapeutics.

Amgen's business strategy centers around delivering innovative medicines for serious illnesses. Key strategic priorities include:

• Investing in R&D to discover and develop first-in-class medicines
• Expanding into new markets and therapeutic areas, particularly rare diseases
• Leveraging strategic acquisitions to strengthen its portfolio and pipeline
• Optimizing its manufacturing network and supply chain
• Developing and commercializing biosimilar products
• Collaborating with payers and other stakeholders to improve healthcare outcomes
• Focusing on environmental sustainability and social responsibility

Amgen's long-term goals include maintaining its leadership position in the biotechnology industry, expanding its global reach, and maximizing the value of its products for patients and stockholders. The company is committed to continuous improvement and innovation to address unmet medical needs and improve patient lives.

Amgen operates in the highly competitive biopharmaceutical industry. The company faces competition from large pharmaceutical companies, generics manufacturers, and other biotechnology companies. Key market trends affecting Amgen's business include increasing pressure on drug pricing and reimbursement, growing demand for biosimilars, and evolving regulatory requirements. Amgen's major competitors include AbbVie, Pfizer, Novartis, Lilly, Regeneron, Sanofi, BMS, and Roche.

• Pricing and Reimbursement Pressures: Amgen's sales depend on coverage and reimbursement from government and commercial third-party payers. Increasing pricing and reimbursement pressures, including government actions to lower drug prices (such as the Inflation Reduction Act), could significantly impact Amgen's profitability.
• Competition: Amgen faces substantial competition from other biopharmaceutical companies, including those developing biosimilars and generics. This competition could affect the pricing and market share of Amgen's products.
• R&D Risks: Successful product development in the biotechnology industry is highly uncertain. Despite significant investments in R&D, Amgen may not be able to develop commercially viable products or obtain regulatory approvals for its product candidates.
• Operational Risks: Amgen's manufacturing operations are concentrated in Puerto Rico and Thousand Oaks, California, making the company vulnerable to natural disasters and other disruptions. Additionally, Amgen relies on third-party suppliers for certain raw materials and components, which could create supply chain vulnerabilities.
• Legal and Regulatory Risks: Amgen's business is subject to extensive regulation by government authorities in the United States and other countries. Changes in laws and regulations, as well as legal proceedings and government investigations, could negatively impact Amgen's business.